Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MANBA | O00462 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6676888 | 1.00 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL15678411 | 1.00 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL12018358 | 1.00 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL18596140 | 1.00 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL2756249 | 1.00 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL7147890 | 1.00 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL1984099 | 1.00 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL2367932 | 1.00 | LMNA (0.41) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL7147304 | 0.91 | LMNA (0.38) | LMNACYP1A2THPOMANBATHRB | |
| SCHEMBL18263599 | 0.91 | LMNA (0.38) | LMNACYP1A2THPOMANBATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5709737-A | AQUEOUS LIQUID VEHICLE, COLORANT, ALCOHOL ADDITIVE; SUITABLE FOR MICROWAVE DRYING PROCESSES | XEROX CORPORATION (US) | 1998-01-20 | — | — | US | claimed |
| US-4804789-A | D-mannite derivatives as starting products for the synthesis of phospholipids | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1989-02-14 | — | — | US | claimed |
| CN-107428665-B | Method for producing (meth) acrylic ester | 东亚合成株式会社 | 2021-10-15 | — | — | CN | disclosed |
| CN-107406363-B | Method for producing (meth) acrylic ester | 东亚合成株式会社 | 2021-10-08 | — | — | CN | disclosed |
| EP-3010488-B1 | STEREOSPECIFIC LIPIDS FOR LOCOREGIONAL THERAPY WITH LONG-TERM CIRCULATING STIMULI-SENSITIVE NANOCARRIER SYSTEMS | THERMOSOME GmbH (DE) | 2021-05-05 | — | — | EP | disclosed |
| CN-107709377-B | Curable composition | 东亚合成株式会社 | 2021-04-20 | — | — | CN | disclosed |
| CN-107709376-B | Curable composition | 东亚合成株式会社 | 2020-10-30 | — | — | CN | disclosed |
| EP-3281933-B1 | (METH)ACRYLATE MANUFACTURING METHOD | TOAGOSEI CO LTD (JP) | 2020-08-19 | — | — | EP | disclosed |
| CN-107148410-B | Cationic lipids for nucleic acid delivery | 日油株式会社 | 2020-04-28 | — | — | CN | disclosed |
| US-10619058-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-14 | — | — | US | disclosed |
| US-10611856-B2 | Curable composition | TOAGOSEI CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| WO-1994019329-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |
| US-5298492-A | Inhibitors of endopeptidase and treatment of cardiovascular disorders | SCHERING CORPORATION (US) | 1994-03-29 | — | — | US | disclosed |
| WO-1994003481-A1 | DIAMINO ACID DERIVATIVES AS ANTIHYPERTENSIVES | SCHERING CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
| EP-0222522-B1 | PLATINUM COORDINATION COMPOUNDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1990-03-14 | — | — | EP | disclosed |
| US-4804789-A | D-mannite derivatives as starting products for the synthesis of phospholipids | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1989-02-14 | — | — | US | disclosed |
| US-4783452-A | ANTITUMOR AGENTS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1988-11-08 | — | — | US | disclosed |
| US-4734225-A | ANTITUMOR AGENTS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1988-03-29 | — | — | US | disclosed |
| US-4709059-A | Process for selective halogenation of primary hydroxyl groups | THE DOW CHEMICAL COMPANY (US) | 1987-11-24 | — | — | US | disclosed |
| EP-0222522-A2 | Platinum coordination compounds | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1987-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611856-B2 | Curable composition | ACR, KAT2B, KAT5 | LMNA 618/4885CYP1A2 4521/4885THPO 538/4885 |
| US-10619058-B2 | Curable composition | ZMYND8, AZI2, KAT2A | LMNA 568/4885CYP1A2 3885/4885THPO 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.